Literature DB >> 2424078

Phytanic acid oxidase activity in cultured skin fibroblasts. Diagnostic usefulness and limitations.

O H Skjeldal, O Stokke, J Norseth, S O Lie.   

Abstract

Patients with Refsum's disease lack the ability to degrade phytanic acid to pristanic acid and CO2. This defect is expressed in fibroblasts from the patients. An assay system for the degradation of phytanic acid in cultured skin fibroblasts is described. The assay makes it possible to single out patients with Refsum's disease from the cob-web of clinically related conditions. The sensitivity is, however, not good enough to diagnose the heterozygous state. A defect of the same pronounced degree as in Refsum's disease is also found in fibroblasts from patients with Zellweger's syndrome, neonatal adrenoleukodystrophy, and infantile Refsum's disease. The radioactive material remaining in the cells after incubation was identified as unmetabolized phytanic acid. No traces of radioactive intermediates could be found in the cells from any of the patient groups. This might indicate that the defects both in Refsum's disease and in the peroxisomal disorders are located either at the same metabolic step or at steps which are closely linked to each other.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2424078     DOI: 10.3109/00365518609083671

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

1.  A new type of chondrodysplasia punctata associated with peroxisomal dysfunction.

Authors:  B T Poll-The; P Maroteaux; C Narcy; P Quetin; M Guesnu; R J Wanders; R B Schutgens; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

2.  Lymphoblastoid cell lines for diagnosis of peroxisome biogenesis disorders.

Authors:  Sabine Grønborg; Ralph Krätzner; Hendrik Rosewich; Jutta Gärtner
Journal:  JIMD Rep       Date:  2011-06-22

3.  A case of Refsum disease with atypical clinical picture in family members.

Authors:  R Marano; P Soliveri; B Garavaglia; A Antonelli; F Girotti
Journal:  Ital J Neurol Sci       Date:  1989-08

4.  Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders.

Authors:  B T Poll-The; O H Skjeldal; O Stokke; A Poulos; F Demaugre; J M Saudubray
Journal:  Hum Genet       Date:  1989-01       Impact factor: 4.132

Review 5.  Zellweger syndrome: biochemical procedures in diagnosis, prevention and treatment.

Authors:  R B Schutgens; R J Wanders; H S Heymans; A W Schram; J M Tager; G Schrakamp; H van den Bosch
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

6.  The deficient degradation of synthetic 2- and 3-methyl-branched fatty acids in fibroblasts from patients with peroxisomal disorders.

Authors:  P P Van Veldhoven; S Huang; H J Eyssen; G P Mannaerts
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

7.  Accumulation of pristanic acid (2, 6, 10, 14 tetramethylpentadecanoic acid) in the plasma of patients with generalised peroxisomal dysfunction.

Authors:  A Poulos; P Sharp; A J Fellenberg; D W Johnson
Journal:  Eur J Pediatr       Date:  1988-02       Impact factor: 3.183

8.  Formic acid is a product of the alpha-oxidation of fatty acids by human skin fibroblasts: deficiency of formic acid production in peroxisome-deficient fibroblasts.

Authors:  A Poulos; P Sharp; H Singh; D W Johnson; W F Carey; C Easton
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.